)
)
Bavarian Nordic Investor Relations Material
Latest events
Q3 2024
Bavarian Nordic
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Bavarian Nordic
Access all reports
Segment Data
Access more data
Revenue by
Products and services
MVA-BN smallpox vaccine
Rabipur/RabAvert
Encepur
Other product sale
Other
Expenses by
Financials
Bavarian Nordic is a clinical-stage biopharmaceutical company that develops and commercializes life-saving vaccines in the areas of cancer and infectious diseases. Its fast-growing portfolio today includes Aeras, an influenza vaccine that has been approved in the United States, Europe, and Canada, and the company is advancing a pipeline of novel, next generation vaccines designed to complement its portfolio. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Key slides for Bavarian Nordic
Q1 2024
Bavarian Nordic
CMD 2024
Bavarian Nordic
Latest articles
)
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
BAVA
Country
🇩🇰 Denmark